Xiaohao Ruan

Xiaohao Ruan

Auto-generated profile, based on publicly available information

Xiaohao Ruan

Department of Urology Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2023 in eLife
Verified
Journal Article
Open access
XRXiaohao Ruan
Xiaohao Ruan
DHDa Huang
Da Huang
YZYongle Zhan
Yongle Zhan
JHJingyi Huang
Jingyi Huang
JHJinlun Huang
Jinlun Huang
Rong NaRong Na
Rong Na
Background: The risk of second primary cancers (SPC) is increasing after the first primary cancers (FPC) are diagnosed and treated. The underlying causal relationship remains unclear.Methods: We conducted a pan-cancer association (26 cancers) study in the Surveillance, Epidemiology, and End Results (SEER) database (non-Hispanic whites). The standardized incidence ratio (SIR) was estimated as the risk of SPCs in cancer survivors based on the incidence in the general population. Furthermore, the causal effect was evaluated by two-sample Mendelian Randomization (MR, 13 FPCs) in the UK Biobank (UKB, n=459,136,, European whites) and robust analysis (radial MR and Causal Analysis Using Summary Effect estimates, CAUSE).Results: We found 11 significant cross-correlations among different cancers after harmonizing SIR and MR results. Whereas only 4 of them were confirmed by MR to have a robust causal relationship. In particular, patients initially diagnosed with oral pharyngeal cancer would have an increased risk of non-Hodgkin lymphoma (SIRSEER = 1.18, 95%Confidence Interval [CI]:1.05–1.31, ORradial-MR=1.21, 95% CI:1.13–1.30, p=6.00 × 10-3; ORcause = 1.17, 95% CI:1.05–1.31, p=8.90 × 10-3). Meanwhile, ovary cancer was identified to be a risk factor for soft tissue cancer (SIRSEER = 1.72, 95%Confidence Interval [CI]:1.08–2.60, ORradial-MR=1.39, 95% CI:1.22–1.58, p=1.07 × 10-3; ORcause = 1.36, 95% CI:1.16–1.58, p=0.01). And kidney cancer was likely to cause the development of lung cancer (SIRSEER = 1.28, 95%Confidence Interval [CI]:1.22–1.35, ORradial-MR=1.17, 95% CI:1.08–1.27, p=6.60 × 10-3; ORcause = 1.16, 95% CI:1.02–1.31, p=0.05) and myeloma (SIRSEER = 1.54, 95%Confidence Interval [CI]:1.33–1.78, ORradial-MR=1.72, 95% CI:1.21–2.45, p=0.02; ORcause = 1.49, 95% CI:1.04–2.34, p=0.02).Conclusions: A certain type of primary cancer may cause another second primary cancer, and the profound mechanisms need to be studied in the future.Funding: This work was in supported by grants from National Natural Science Foundation of China (Grant No. 81972645), Innovative research team of high-level local universities in Shanghai, Shanghai Youth Talent Support Program, intramural grant of The University of Hong Kong to Dr. Rong Na, and Shanghai Sailing Program (22YF1440500) to Dr. Da Huang.

18 January 2024 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
XRXiaohao Ruan
Xiaohao Ruan
NZNing Zhang
Ning Zhang
DWDawei Wang
Dawei Wang
JHJingyi Huang
Jingyi Huang
JHJinlun Huang
Jinlun Huang
Rong NaRong Na
Rong Na
Background: The status of prostate-specific antigen (PSA) screening is unclear in China. Evidence regarding the optimal frequency and interval of serial screening for prostate cancer (PCa) is disputable. Objective: This study aimed to depict the status of PSA screening and to explore the optimal screening frequency for PCa in China. Methods: A 13-year prospective cohort study was conducted using the Chinese Electronic Health Records Research in Yinzhou study’s data set. A total of 420,941 male participants aged ≥45 years were included between January 2009 and June 2022. Diagnosis of PCa, cancer-specific death, and all-cause death were obtained from the electronic health records and vital statistic system. Hazard ratios (HRs) with 95% CIs were estimated using Cox regression analysis. Results: The cumulative rate of ever PSA testing was 17.9% with an average annual percent change (AAPC) of 8.7% (95% CI 3.6%-14.0%) in the past decade in China. People with an older age, a higher BMI, higher waist circumference, tobacco smoking and alcohol drinking behaviors, higher level of physical activity, medication use, and comorbidities were more likely to receive PSA screening, whereas those with a lower education level and a widowed status were less likely to receive the test. People receiving serial screening ≥3 times were at a 67% higher risk of PCa detection (HR 1.67; 95% CI 1.48-1.88) but a 64% lower risk of PCa-specific mortality (HR 0.36; 95% CI 0.18-0.70) and a 28% lower risk of overall mortality (HR 0.72; 95% CI 0.67-0.77). People following a serial screening strategy at least once every 4 years were at a 25% higher risk of PCa detection (HR 1.25; 95% CI 1.13-1.36) but 70% (HR 0.30; 95% CI 0.16-0.57) and 23% (HR 0.77; 95% CI 0.73-0.82) lower risks of PCa-specific and all-cause mortality, respectively. Conclusions: This study reveals a low coverage of PSA screening in China and provides the first evidence of its benefits in the general Chinese population. The findings of this study indicate that receiving serial screening at least once every 4 years is beneficial for overall and PCa-specific survival. Further studies based on a nationwide population and with long-term follow-up are warranted to identify the optimal screening interval in China.

17 August 2022 in Cancer Medicine
Verified
Journal Article
Open access
JHJingyi Huang
Jingyi Huang
DHDa Huang
Da Huang
XRXiaohao Ruan
Xiaohao Ruan
JHJinlun Huang
Jinlun Huang
DXDanfeng Xu
Danfeng Xu
Rong NaRong Na
Rong Na
Background: Legislation of cannabis use has been approved in many European and North American countries. Its impact on urological cancers is unclear. This study was conducted to explore the association between cannabis use and the risk of urological cancers.Methods: We identified 151,945 individuals with information on cannabis use in the UK Biobank from 2006 to 2010. Crude and age‐standardized incidence ratios of different urological cancers were evaluated in the entire cohort and subgroups. Cox regression was performed for survival analysis.Results: Previous use of cannabis was a significant protective factor for renal cell carcinoma (HR = 0.61, 95%CI:0.40–0.93, p = 0.021) and prostate cancer (HR = 0.82, 95%CI:0.73–0.93, p = 0.002) in multivariable analysis. The association between previous cannabis use and both renal cell carcinoma and bladder cancer was only observed in females (HRRCC = 0.42, 95%CI:0.19–0.94, p = 0.034; HRBCa = 0.43, 95%CI:0.21–0.86, p = 0.018) but not in men. There was no significant association between cannabis use and testicular cancer incidence. Mendelian randomization demonstrated a potential causal effect of cannabis use on a lower incidence of renal cell carcinoma.Conclusions: Previous use of cannabis was associated with a lower risk of bladder cancer, renal cell carcinoma, and prostate cancer. The inverse association between cannabis and both renal cell carcinoma and bladder cancer was only found in females but not in males.

22 August 2022 in The Prostate
Verified
Journal Article
Closed access
XRXiaohao Ruan
Xiaohao Ruan
DHDa Huang
Da Huang
JHJingyi Huang
Jingyi Huang
DXDanfeng Xu
Danfeng Xu
Rong NaRong Na
Rong Na

12 July 2021 in The Prostate
Verified
Journal Article
Open access
PDF file
DHDa Huang
Da Huang
XRXiaohao Ruan
Xiaohao Ruan
YWYishuo Wu
Yishuo Wu
XLXiaoling Lin
Xiaoling Lin
JHJingyi Huang
Jingyi Huang
Rong NaRong Na
Rong Na
Background: Prostate health index (phi), a derivative of [−2]proPSA (p2PSA), has shown better accuracy than prostate‐specific antigen (PSA) in prostate cancer (PCa) detection. The present study was to investigate whether previously identified PSA‐associated single nucleotide polymorphisms (SNPs) influence p2PSA or phi levels and lead to potential clinical utility.Methods: We conducted an observational prospective study with 2268 consecutive patients who underwent prostate biopsy in three tertiary medical centers from August 2013 to March 2019. Genotyping data of the 46 candidate genes with a ± 100 kb window were tested for association with p2PSA and phi levels using linear regression. Multivariable logistic regression models were performed and internally validated using repeated tenfold cross‐validation. We further calculated personalized phi cutoff values based on the significant genotypes. Discriminative performance was assessed using decision curve analysis and net reclassification improvement (NRI) index.Results: We detected 11 significant variants at 19q13.33 which were p2PSA‐associated independent of PCa. The most significant SNP, rs198978 in KLK2 (Pcombined = 5.73 × 10−9), was also associated with phi values (Pcombined = 3.20 × 10−6). Compared to the two commonly used phi cutoffs of 27.0 and 36.0, the personalized phi cutoffs had a significant NRI for PCa ranged from 5.23% to 9.70% among men carrying variant types (all p < .01).Conclusion: Rs198978, is independently associated with p2PSA values, and can improve the diagnostic ability of phi for PCa using personalized cutoff values.

9 August 2024 in Cancer Medicine
Verified
Journal Article
Open access
RSRuofan Shi
Ruofan Shi
DHDa Huang
Da Huang
JYJiaqi Yan
Jiaqi Yan
XRXiaohao Ruan
Xiaohao Ruan
JHJingyi Huang
Jingyi Huang
Rong NaRong Na
Rong Na
Background: Anticipating the postoperative pathological stage and potential for adverse features of prostate cancer (PCa) patients before radical prostatectomy (RP) is crucial for guiding perioperative treatment.Methods: A cohort consisting of three sub‐cohorts with a total of 709 patients has been enlisted from two major tertiary medical centres in China. The primary assessment parameters for adverse pathological features in this study are the pathological T stage, the AJCC prognostic stage groups and perineural invasion (PNI). Logistic regression analyses were performed to investigate the relationship between prostate specific antigen (PSA), its derivatives (incluing Prostate Health Index, phi and phi density, phiD), and the pathological outcomes after RP.Results: Both phi and phiD showed a significant association with pathologic T stage of pT3 or above (phi, adjusted OR, AOR = 2.82, 95% confidence interval, 95% CI: 1.88–4.23, p < 0.001; phiD, AOR = 2.47, 95% CI: 1.76–3.48, p < 0.001) and PNI (phi, AOR = 2.15, 95% CI: 1.39–3.32, p < 0.001; phiD, AOR = 1.94, 95% CI: 1.38–2.73, p < 0.001). In a subgroup analysis with a total PSA value <10 ng/mL, phi and phiD continued to show a significant correlation with pT3 or above (phi, AOR = 4.70, 95% CI: 1.29–17.12, p = 0.019; phiD, AOR = 3.44, 95% CI: 1.51–7.85, p = 0.003), and phiD also maintained its predictive capability for PNI in this subgroup (AOR = 2.10, 95% CI: 1.17–3.80, p = 0.014). Sensitivity analysis indicated that the findings in the combined cohort are mainly influenced by one of the sub‐cohorts, partially attributable to disparities in sample sizes between sub‐cohorts. Combined analysis of phi(D) and multiparametric MRI (mpMRI) data yielded similar results.Conclusions: Preoperative measurement of serum phi and phiD is valuable for predicting the occurrence of adverse pathological features in Chinese PCa patients after RP.